The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. - Giudice E; Huang TT; Nair JR; Zurcher G; McCoy A; Nousome D; Radke MR; Swisher EM; Lipkowitz S; Ibanez K; Donohue D; Malys T; et al. (Nature communications, 2024)